International multicenter evaluation of autoantibodies to ribosomal P proteins
International multicenter evaluation of autoantibodies to ribosomal P proteins
复制标题
DOI：
10.1128/cvi.13.1.77-83.2006
复制
发表时间：
2006-01-01
影响因子：
--
通讯作者：
Fritzler, MJ
中科院分区：
文献类型：
--
作者：
Mahler, M;Kessenbrock, K;Fritzler, MJ
核糖体磷酸化蛋白（Rib-P）自身抗体是系统性红斑狼疮（SLE）患者的血清学特征。据报道，SLE患者中抗rib - p抗体的患病率从10%到40%不等，在亚洲患者中更高。观察到的频率变化可能与许多因素有关，但在很大程度上取决于用于检测自身抗体的测试系统。抗rib - p与SLE中枢神经系统受累和神经精神表现的关联一直存在争议。在目前的国际多中心研究中，我们评估了一种新的基于重组Rib-P多肽的Rib-P特异性酶联免疫吸附试验的临床准确性。结果显示，947例SLE患者的检测结果为21.3%，而1113例对照患者的检测结果仅为0.7% （P < 0.0001）。敏感性、特异性、阳性预测值、阴性预测值和诊断效率分别为21.3%、99.3%、95.6%、62.2%和65.3%。在各参与中心进行评估时，发现抗rib - p抗体的患病率呈下降趋势，如下：中国(35%)>波兰(34%)>日本(28%)>美国(26%)>德国（弗莱堡；23.3%）>丹麦(20.5%)>德国（柏林；19%）>墨西哥(15.7%)>以色列(11.7%)>巴西(10%)>加拿大（8%）。本研究的大量数据表明，抗rib - p抗体的流行可能不限于患者的遗传背景或检测系统，而可能取决于地区实践差异和患者选择。我们证实先前报道的抗核糖体抗体与临床症状和血清学结果的关联。值得注意的是，我们发现rib -p阳性狼疮患者血清炎的发生率较低。
Autoantibodies to the ribosomal phosphoproteins (Rib-P) are a serological feature of patients with systemic lupus erythematosus (SLE). The reported prevalence of anti-Rib-P antibodies in SLE ranges from 10 to 40%, being higher in Asian patients. The variation in the observed frequency may be related to a number of factors but is dependent in large part on the test system used to detect the autoantibodies. An association of anti-Rib-P with central nervous system involvement and neuropsychiatric manifestations of SLE has been controversial. In the present international multicenter study, we evaluated the clinical accuracy of a new sensitive Rib-P-specific enzyme-linked immunosorbent assay based on recombinant Rib-P polypeptides. The results showed that 21.3% of 947 SLE patients, but only 0.7% of 1,113 control patients, had a positive test result (P < 0.0001). The sensitivity, specificity, positive and negative predictive values, and diagnostic efficiency were determined to be 21.3%, 99.3%, 95.6%, 62.2%, and 65.3%, respectively. When evaluated in the context of participating centers, the prevalence of anti-Rib-P antibodies was found in descending frequency, as follows: China (35%) > Poland (34%) > Japan (28%) > United States (26%) > Germany (Freiburg; 23.3%) > Denmark (20.5%) > Germany (Berlin; 19%) > Mexico (15.7%) > Israel (11.7%) > Brazil (10%) > Canada (8%). The substantial data from this study indicate that the prevalence of anti-Rib-P antibodies may not be restricted to the genetic background of the patients or to the detection system but may depend on regional practice differences and patient selection. We confirm previously reported associations of antiribosomal antibodies with clinical symptoms and serological findings. Remarkably, we found a lower occurrence of serositis in Rib-P-positive lupus patients.